Envision Pharma Group

Discover how our AI platform, OKRA.ai, has been used to empower continuous insights by evolving from manual reports to automated AI solutions for actionable data. Our case study showcases the value #OKRA delivers to our clients, including: 🚀 80% reduction in time to insight ⏰ Time to client action: 1 month versus 5 months ⚙️ 100% automation 🔄 Closed feedback loop 🎯 AI deployment in just 4 weeks Download the case study 👉 https://lnkd.in/dn2n7fyR

We’re excited to share a thought-provoking pharmaphorum article by Dr. Yahya Anvar, General Manager and Head of OKRA.ai, "Going beyond the hype: Embracing AI for strategic advantage.” In this insightful piece, Dr. Anvar examines the critical challenges facing the life sciences sector, such as the rapid pace of AI adoption, the knowledge gaps within medical affairs teams, and the necessary steps to upskill these teams for effective AI implementation. He also explores how to align AI initiatives with the strategic priorities of life sciences organizations. Check out the article for more information: https://lnkd.in/eYPGjBkc.

We are excited to bring you an unmissable panel at the Alliance for Regenerative Medicine's #CellandGene Meeting on the Mesa: "Anatomy of a CGT Launch: Operationalizing Cell and Gene Therapy," hosted by Kyle Felmet, VP, Specialty Commercialization, at Two Labs (an Envision Pharma Company). Launching cell and gene therapies is complex, and we’re diving deep with industry experts who’ve mastered the art of: - Tackling complex reimbursement landscapes and negotiating with payers - Streamlining patient-specific logistics to ensure timely and safe delivery - Navigating regulatory hurdles that can challenge even the most seasoned teams - Developing launch strategies that drive success from clinical trials through post-launch - Coordinating cross-functional teams to keep everyone aligned and moving forward This session will offer real-world insights and proven strategies that can help attendees bring groundbreaking therapies to patients more effectively. #cellandgene #meetingonthemesa #lifesciences

Ready to improve the way you conduct literature research and draft publications? Check out this real-time showcase of Smart Citations within iEnvision. This insightful webinar with Josh Nicholson (Research Solutions) and Jon Edwards (Envision Pharma Group) will tackle the common challenges when citing publications in medical affairs. https://hubs.li/Q02MX_r90 #medpubs #technology #literatureresearch

The true value of AI in medical affairs lies not in the platform, but in how it's integrated into strategy and operations. 4Sight by Envision is more than a platform; it's a holistic approach that aligns cutting-edge AI technology with empowered people and optimized processes. This synergy drives the entire insights journey, from data analysis to strategic decision-making, achieving exceptional medical affairs performance.   In the final instalment of our 4Sight series, we unveil the quantifiable impact of this comprehensive approach. Discover how 4Sight delivers game-changing results, empowering teams to: ✅ Accelerate insights ✅ Drive efficiency ✅ Make strategic decisions   Read our latest blog post now.  👉 https://lnkd.in/e5fCEJpx   #HealthcareAI #MedicalInnovation #MedicalAffairs

At Envision Pharma Group, we're at the forefront of integrating AI into real-world evidence (RWE), transforming how healthcare stakeholders approach value and access. By utilizing advanced natural language processing (NLP), we’re turning vast, unstructured data sources into actionable insights that drive more informed decisions in patient care and market access. In our latest piece, Suki Kandola, Global Head of Commercial Strategy, Value & Access, and Yahya Anvar, General Manager, Head of OKRA.ai, discuss how AI-powered RWE is not just enhancing our understanding of treatment outcomes, but also addressing key regulatory hurdles and accelerating access to effective therapies. https://lnkd.in/eZRVpyvV #OKRA #MarketAccess #ValueandAccess #RealWorldEvidence #AIinHealthcare

In an article with Drug Target Review, Rebecca Goldstein, PhD, CMPP, Senior Principal, Strategic Consulting, explores how anchoring drug development programs to patient experiences can help navigate the evolving oncology landscape. Discover how patient-centered approaches are reshaping the landscape and the role of regulatory bodies like the FDA and EMA in integrating patient input through patient-reported outcomes and real-world evidence initiatives. Read the full article here. 👉🔗 https://lnkd.in/gUkjJrkR. #Oncology #DrugDevelopment #HealthcareInnovation

In the fast-paced world of pharma, generating and acting on medical insights is a game-changer. In the third part of our 4Sight series, we explore the critical role of process in the 4Sight approach, empowering organizations to transform AI-generated insights into strategic actions.   Discover how to enhance your insights process by: 🔍 Pinpointing critical questions 🤝 Fostering cross-functional collaboration 🎯 Engaging key stakeholders 🔚 Creating a sustainable communication loop Learn more about our proven approach to transforming medical affairs data into actionable insights through our blog. 👉 https://lnkd.in/esv2H8M9   #HealthcareAI #MedicalInnovation #MedicalAffairs

How can we harness the full potential of AI in pharma? We believe it starts with breaking down data silos and fostering true interoperability. Jim Streeter, Envision's President of Technology and Chief Technology Officer, explains in his Pharmaceutical Executive article that by integrating historical, predictive, and real-time data into a unified ecosystem, we ensure that AI provides the reliable insights needed to drive better decisions. Our focus is on making AI a seamless part of daily workflows, empowering teams to concentrate on what truly matters—bringing life-changing therapies to patients faster and more efficiently. https://lnkd.in/ewgSTYBS #AI #LifeSciences #Data

In honor of #NationalPatientAdvocacyDay, Envision Pharma Group recognizes patients' vital role in shaping healthcare. We are resharing our blog from Jessica Krauser, Jasmine Patel, MPH, and Amanda Boughey that looks at how patient insights are influencing the development of new medicines: - Patient-focused drug development has a 19% higher success rate. - Involving patients early can speed up product launches by 2.5 years. - Patient advocacy has led to important changes in clinical trials and regulations. However, there are still challenges: - Regulatory hurdles - Proving long-term benefits - Budget limits - Need for cultural change within organizations We are committed to overcoming these challenges to develop better healthcare solutions. Read our full analysis on why patient involvement matters in medicine development: https://lnkd.in/eP6XJzpC #PatientAdvocacy #MedicineDevelopment #LifeSciences